Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM6B9HP)

Drug Name

Apomine Drug Info

Synonyms

Apomine; SR-45023A; UNII-JQ95208805; JQ95208805; SR-9223i; SR 45023A; APB-231-A2; SKF 99085; F-99085; 126411-13-0; SCHEMBL1648488; AC1L423G; DB12276; 4-[2,2-bis[di(propan-2-yloxy)phosphoryl]ethyl]-2,6-ditert-butylphenol; tetraisopropyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-biphosphonate; Phosphonic acid, (2-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethylidene)bis-, tetrakis(1-methylethyl); SK&F-99085; 2-(3,5-Di-tert-butyl-4-hydroxyphenyl)ethylidene-1,1-diphosphonic acid tetraisopropyl ester; SR-45023A (Apomine)

Indication

Disease Entry	ICD 11	Status	REF
Osteopetrosis	LD24.10	Phase 2	[1]

Cross-matching ID

PubChem CID: 176405
CAS Number: CAS 126411-13-0
TTD Drug ID: DM6B9HP

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Farnesoid X-activated receptor (FXR)	TTS4UGC	NR1H4_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Farnesoid X-activated receptor (FXR)	DTT	NR1H4	9.173	5.722	7.333	6.967

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Osteopetrosis

ICD Disease Classification

LD24.10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Farnesoid X-activated receptor (FXR)	DTT	NR1H4	5.72E-01	0.39	1.68

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs. 2006 Jan;24(1):89-94.
2	The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.